Vanda Pinto, PhD, science writer —

Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.

Articles by Vanda Pinto

Laser Therapy May Treat Symptoms in Dominant DEB: Case Report

Pulsed dye laser therapy — a treatment commonly used for skin conditions such as certain types of birthmarks and scars — resulted in fewer blisters and eased erythema (reddening of the skin) in a 19-year-old girl with dominant dystrophic epidermolysis bullosa (DEB), according to a recent case report. The…

Methotrexate Might Help in Skin Healing in RDEB, Study Suggests

More than 2,000 transcripts — RNA molecules that derive from DNA and carry instructions for protein production — were found to be differentially produced between intact skin and wounds in people with recessive dystrophic epidermolysis bullosa (RDEB). Based on these findings, computer simulations identified the prescription medication methotrexate…

Cannabinoids Ease EB Pain and Itchiness, Patients Say in Survey

Cannabinoid medications, those derived from cannabis, improve overall well-being and ease perceptions of pain and itchiness, more than 90% of epidermolysis bullosa (EB) patients who responded to a global survey reported. About 80% also reported taking fewer opioids, or stopping opioid use, to help with disease symptoms after starting on…

New Mutations Found in Children With Recessive DEB in Vietnam

Three new mutations in the COL7A1 gene and five very rare variants were identified for the first time in children with recessive dystrophic epidermolysis bullosa (DEB) in Vietnam, a study reported. These findings expand “the spectrum of COL7A1 mutations” and may have implications for the genetic counseling of patients…

IgA EBA Much Different From Linear IgA Bullous Dermatosis

IgA epidermolysis bullosa acquisita (EBA) differs significantly from another skin condition known as linear IgA bullous dermatosis (LABD), and should be considered a separate disease, a German study suggests. In addition, the research highlights the importance of identifying the exact autoantigen, or targeted protein, in each condition, so that…